

Detection of A2142C, A2142G, and A2143G Mutations in 23s *rRNA* Gene Conferring Resistance to Clarithromycin among *Helicobacter pylori* Isolates in Kerman, Iran

Hamid Abdollahi¹, Mohammad Savari¹,
Mohammad Javad Zahedi²,
Sodaif Darvish Moghadam²,
Mehdi Hayatbakhsh Abasi²

Abstract

Background: Clarithromycin resistance in *Helicobacter pylori* has been found to be associated with point mutations in 23s *rRNA* gene leads to reduced affinity of the antibiotic to its ribosomal target or changing the site of methylation. The aim of this study was to determine the most important point mutations in 23s *rRNA* gene in *H. pylori* that are closely related to clarithromycin resistance among such isolates.

Methods: Sixty three *H. pylori* isolates, obtained from gastric biopsy specimens in Kerman, Iran, were used to evaluate their susceptibility to clarithromycin by disk diffusion test, and to detect the most common point mutations in 23s *rRNA* gene associated with clarithromycin resistance by Polymerase chain reaction-amplification and restriction fragment length polymorphism (PCR-RFLP) and 3'-mismatch PCR.

Results: 31.7% of the *H. pylori* isolates were resistant to clarithromycin, and each of the resistant isolate had at least one of the most common point mutations in 23s *rRNA* gene associated with clarithromycin resistance.

Conclusion: According to our results three common point mutation in 23s *rRNA* gene in *H. pylori* are closely related to clarithromycin resistance. There was an absolute relation between 23s *rRNA* gene point mutations and clarithromycin resistance in this study. *Helicobacter pylori* resistance to clarithromycin can cause failure in the eradications of the bacteria. The resistance of the bacteria is expanding in most parts of the world including Iran.

Iran J Med Sci 2011; 36(2): 104-110.

Keywords • Clarithromycin • point mutations • *Helicobacter pylori*

Introduction

Helicobacter pylori is a microaerophilic gram-negative organism involved in many digestive system diseases, such as peptic ulcer, gastritis, or mucosa-associated lymphoid tissue (MALT) lymphoma, or acting as a risk factor in the development of gastric cancer.¹ The prevalence of *H. pylori* infection varies greatly among different countries, as in many developing countries it is over 70%, while in most industrialized nations it is 20% to 50%.²

¹Department of Medical Microbiology, Virology & Immunology,
²Physiology Research Center and Department of Gastroenterology, Kerman University of Medical Sciences, Kerman, Iran.

Correspondence:

Mohammad Savari MSc,
Department of Medical Microbiology,
School of Medicine,
Kerman University of Medical Sciences,
Kerman, Iran.
Tel/Fax: +98 341 3221665
Email: mohammad1318@yahoo.com
Received: 16 October 2010
Revised: 16 January 2011
Accepted: 27 February 2011

Eradication of *H. pylori* is an important component of treatments for peptic ulcer disease and other gastrointestinal disorders.³ Triple or quadruple therapy regimen containing a proton-pump inhibitor (PPI) and antibiotics, mainly clarithromycin and metronidazole, are currently in use.⁴ The inhibition of protein synthesis is the functional mechanisms of the macrolides, causing the separation of peptidyl-tRNA from the ribosome during the elongation reaction.⁵

One of the most common components of the *H. pylori* infections therapy regimens is clarithromycin. The resistance to macrolides such as clarithromycin in *H. pylori* has been demonstrated to occur at different rates (1 to 10%) in different countries, and is an important cause of *H. pylori* therapeutics regimens failure. Furthermore, macrolide-resistant *H. pylori* mutants are simply obtained by in vitro selection.⁵

Macrolide resistance is caused by several mechanisms such as the lack of macrolide binding to the ribosomal target, inactivation of the macrolides by enzymes, reduced or lack of bacterial membrane permeability, and macrolides active efflux.⁵ The widespread use of clarithromycin for the treatment of *H. pylori* infection has resulted in the development of resistance.⁶ Clarithromycin resistance (Cla^R) of *H. pylori* is mainly caused by point mutations of the genomic 23s *rRNA*, the main component of the 50S subunit, mostly at position 2142/43 (A2142 to G/C/T; A2143 to G/C) in the peptidyl-transferase region of the V domain, thereby preventing drug binding. Cla^R is increasing due to widespread use of macrolides for other diseases in the western world.⁷

There are some methods to detect the point mutations in genes such as sequencing, and amplification and restriction fragment length polymorphism (RFLP). In this study we used the RFLP method to detect the point mutations in 23s *rRNA* gene in our local *H. pylori* isolates.⁸ Clarithromycin is recognized as the key antibiotic for the treatment of *H. pylori* infections, as has a powerful bactericidal effect in vitro compared with the other available macrolides.⁹ Therefore, the present study aimed at evaluating the Cla^R rates in local *H. pylori* isolates and the probable molecular mechanisms of such a resistance. Specifically, the study aimed at determining the most important point mutations in 23s *rRNA* gene that are closely related to clarithromycin resistance among *H. pylori* isolates in Kerman, Iran.

Materials and Methods

Bacteria

Sixty three *H. pylori* isolates were obtained

from 191 patients' biopsy samples referred to the Endoscopy Division Unit of Afzalipour Hospital in Kerman, Iran. The biopsy samples were cultivated in Brucella Agar medium (Merck, Germany) supplemented with 10% defibrinated sheep blood (Darvash, Iran) and three antibiotics including Vancomycin (10 mg/l), Amphotricin B (10 mg/l) and Trimetoprim (5 mg/l) (Sigma, USA). The inoculated plates were incubated at 37°C under microaerophilic atmosphere provided by anerocult C (Merck, Germany) for 3-5 days. The isolates were recognized as *H. pylori* by urease, catalase, oxidase positive and gram negative staining tests.¹⁰

Antibiotic Susceptibility Tests

The susceptibility of the isolates to clarithromycin was evaluated by disc diffusion method. There is no an standard method to evaluate the susceptibility of *H. pylori* to antibiotics. We used the clinical and laboratory standards institute (CLSI) -recommended method called Modified Disc Diffusion method. In this method a microbial suspension with turbidity equals to four McFarland (12 x10⁸ CFU/ml) and cultivated in Muller-Hinton agar (Merck, Germany) supplemented with 10% defibrinated sheep blood (Darvash, Iran). The 2 µg clarithromycin disc (Mast, England) were placed in the plates and incubated in 37°C under microaerophilic atmosphere for three days. Any inhibition zone was considered susceptible.^{10,11}

DNA Extraction

DNA was extracted from all 63 *H. pylori* isolates using Bioneer genomics kit for DNA extraction (Bioneer, South Korea) according to the manufacturer's instruction.

Amplification and Restriction Fragment Length Polymorphism (RFLP)

Two sets of primers were used in this study (table 1).

Table 1: Primers used for amplifications. Primers CLA 18 and CLA 21 were used in polymerase chain reaction-amplification and restriction fragment length polymorphism (PCR-RFLP) to obtain a 1.4 kbp amplified fragment. Primers CLA 18 and CLA 3 were used in 3'-mismatched PCR to obtain a 700 bp amplified fragments.

Set 1			
Cla18	AGTCGGGACCTAAGGCGAG	1400 bp	7
Cla21	TTCCCGCTTAGATGCTTTCAG		
(set2)			
Cla18	AGTCGGGACCTAAGGCGAG	700 bp	11
Cla3	AGGTCCACCACGGGTCTTG		

The first set (cla18, cla21) was used to amplify a 1400 bp fragment from an internal region of 23s *rRNA* gene followed by digestion with

BsaI & *MbolI* (Fermentas, Lithuania). The 1400 bp fragment normally has one restriction site for *BsaI* enzyme. If the gene is wild type, the enzyme produces a 1000 bp and a 400 bp fragments.

If the A2143G point mutation occurs in 1400 bp fragment, the enzyme find two restriction sites and produces three fragments: a 700 bp, a 400 bp, and a 300 bp one. The 1400 bp fragment normally has no restriction site for *MbolI* enzyme, therefore, if the gene is wild type, the 1400 bp remains undigested. But, if the A2142G point mutation exist, the enzyme find one restriction site in the 1400 bp fragment and digest it to two 700 bp fragments that look as one overlapping band in electrophoresis gel.⁷

The second set (cla18, cla3) was used to do 3'-mismatch PCR to detect A2142C point mutation. In this case, if the gene was of wild type there was no fragment, and if the A2142C point mutation took place, a 700 bp fragment was produced.¹²

Polymerase chain reaction condition was as follows for the amplification of the 1400 bp fragment: reactions were carried out in Primus thermo cycler (MWG-Biotech, Germany) in 50 µl mixtures containing 25 µl PCR master mix (CinnaGen Inc, Iran), 19 µl sterile deionized water, two µl template DNA and two µl of each oligonucleotide primer (4 µl totally). Initial denaturation at 94°C for five min followed by 30 cycles of denaturation at 94°C for one min, annealing for one min at 58°C, extension at 72°C for one min. The final extension step was extended to five min at 72°C.

The RFLP protocol was as follows: 10 µl of the 1400 bp fragment was added to two PCR microtubes, and five units of each enzyme was added to the micritubes and incubated at 37°C for 16 hours.

3'-mismatch PCR condition was as follow: reactions were carried out in Primus thermo cycler (MWG-Biotech, Germany) in 25 µl mixtures containing 12 µl PCR master mix (CinnaGen Inc, Iran), 10 µl sterile deionized water, one µl template DNA and one µl of each oligonucleotide primer. Initial denaturation at 94°C for five min followed by 30 cycles of denaturation at 94°C for one min, annealing for one min at 55°C, extension at 72°C for one min. The final extension step was extended to five min at 72°C.

Electrophoresis

The PCR products were separated on 1.5% and the PCR-RFLP products were separated on 2% agarose gels (Cinna gen, Iran) after being stained with ethidium bromide (Merck, Germany) in TBE 1X (Tris/borate/EDTA) buffer under 100 volts electricity flow. Bands were visualized under UV gel documentation and photographed.

Results


Twenty out of 63 (31.7%) of the *H. pylori* isolates were resistant to clarithromycin. There was no significant relation between gender, age or the history of antibiotic consumption by the patients and resistance to calrithromycin. All of the 20 Cla^R isolates had at least one of the three common point mutation in 23s *rRNA* gene, while none of the Cla^S isolates had such a point mutation (table 2).

Table2: The frequency and (rate) of clarithromycin susceptibility test for *H. pylori* isolates in both resistant and sensitive isolates in Kerman, Iran.

CLA sus-ceptibility	Number (%)	23 s <i>rRNA</i> point mutation	Number (%)
R	20 (31.7%)	+	20 (100%)
		-	0 (0%)
S	43 (69.3%)	+	0 (0%)
		-	43 (100%)


CLA: Clarithromycin, R: Resistant, S: sensitive

All of the 63 *H. pylori* isolates were positive for the 1400 bp fragment (figure1). Fifteen percent of the Cla^R isolates (three out of 20 isolates) had the A2143G point mutation (figure 2). There was a significant relation between the gender of the patients and the A2143G point mutation. Three out of 38 (7.9%) of the strains isolated from the female population had this point mutation, whereas no such a mutation was found in the strains isolated from the male population. There was no significant relation between age or the history of antibiotics consumption and the A2143G point mutation.



Line 1:HindIII/EcoRI 21Kbp DNA marker (fermentas); Line 2: Negative control; Line 3-7: Different samples


Figure 1: Gel electrophoresis of 1400 bp fragment PCR products from 23s *rRNA* gene for RFLP. All 63 *H. pylori* isolates were positive.



Line 1: 3000 bp DNA marker (fermentas); Line 2: Negative control (only enzyme); Line 3: only PCR product (1400 bp fragment); Line 4, 5, 6, 7, 8: 1400 bp fragment+Bsal; Line 4, 8: clarithromycin-sensitive *H. pylori* isolates; Line 5, 6, 7: clarithromycin-resistant *H. pylori* isolates.

Figure 2: PCR-RFLP patterns of 1400 bp fragments after digestion with Bsal enzyme in order to detect A2143G point mutation in 23s *rRNA* gene.


Fifty five percent of the Cla^R isolates (11 out of 20 isolates) had the A2142G point mutation (figure 3). There was no significant relation between gender, age or the history of antibiotics consumption of the patients and this mutation.



Line1: 3000 bp DNA marker (fermentas); Line 2: Negative control (only enzyme); Line 3: only PCR product (1400 bp); Line 4, 5, 6, 7, 8: 1400 bp fragment+MboII; Line 4, 8: clarithromycin-sensitive *H. pylori* isolates; Line 5, 6, 7: clarithromycin-resistant isolates

Figure 3: PCR-RFLP patterns of the 1400 bp fragments digested with MboII enzyme in order to detect A2142G point mutation in 23s *rRNA* gene.

Thirty percent of the Cla^R isolates (six out of 20 isolates) were positive for the A2142C point mutation (figure 4). There was no significant relation between age, gender or the history of antibiotics consumption of the patients and this mutation.



Line1: 1000 bp DNA marker (fermentas); Line 2: Negative control; Line 3, 5, 7, 8: clarithromycin-resistant *H. pylori* isolates without A2142G or A2143G; Line 4: clarithromycin-sensitive *H. pylori* isolates; Line 6: Cla^R *H. pylori* isolates with A2143G mutation

Figure 4: Gel electrophoresis of 3'-mismatch PCR products in order to detect A2142C point mutation in 23s *rRNA* gene.

The A2142C point mutations occurred only in Cla^R isolates without A2142G or A2143G (table 3).

Discussions

Resistance of *H. pylori* to antibiotics has been increasing in most parts of the world including Iran.^{11,13-15} Clarithromycin resistance is a serious concern for doctors who are using the drug as one of the most important therapeutic components for *H. pylori*-induced gastric ulcer. There are ever-increasing requests from physicians for a reliable standard antimicrobial susceptibility test for *H. pylori* against clarithromycin, but that would be hard to do because of its fastidious properties and its time-consuming culture. Furthermore, success in *H. pylori* culture is dependent on the microbiology laboratory technicians' skills.¹⁶ Clarithromycin

Table3: Results obtained with the PCR-RFLP and the 3'-mismatched PCR methods for the clinical isolates tested according to the clarithromycin resistance.

mutation	Number (%)	Digestion with: Bsal/MboII	3'mismatch PCR	Cla susceptibility
A2143G	3 (15%)	+/-	-	Cla ^R
A2142G	11 (55%)	-/+	-	Cla ^R
A2142C	6 (30%)	-/-	+	Cla ^R

CLa: Clarithromycin, R: Resistant

resistance rates are varied across the world. For example Elviss et al in London reported 11% resistance to clarithromycin,¹⁷ or Bagalan et al announced 27.6% resistance.¹⁸ Also, the rate of clarithromycin resistance varies in different cities in Iran. For example Kohanteb et al reported 9.4% resistance in Shiraz (2007),¹⁹ while Mohammadi et al showed 20% resistance to clarithromycin in Tehran (2005), and in more recent studies Siyavoshi et al (2010) in Tehran reported 7.3% resistance.^{11,15}

Clarithromycin is a macrolide, that due to its high prices, was not used commonly in Iran in the past years. However, after its production in the country in recent years, it has been used routinely in the treatment of *H. pylori* infections. So, the emergence of Cla^R isolates is inevitable. It is also has been shown that countries with a high consumption of other macrolides have a higher rates of clarithromycin resistance.²⁰ Macrolides such as erythromycin and clarithromycin inhibit nascent peptide chain elongation by interacting with the 50S ribosomal subunit and stimulating the release of peptidyl-tRNA from the A site.²¹ Biochemical studies have demonstrated a direct interaction of clarithromycin and its chief metabolite, 14-hydroxyclearithromycin, with 50S ribosomal subunits isolated from *H. pylori*.^{22,23} The antibacterial activity of clarithromycin is better than that of erythromycin. One reason for such a difference is the synergistic phenomenon between clarithromycin and one its metabolites 14-hydroxyclearithromycin, which leads to a considerable post antibiotic effect. The second reason is higher hydrophobicity of clarithromycin, which leads to a better penetration through the cell membranes than that of erythromycin. The third reason is clarithromycin activity, which is less influenced by acidity than that of erythromycin.²³

Versalovic and colleagues were the first to announce that the clarithromycin resistance of *H. pylori* was associated with a point mutation in the V domain of 23S *rRNA*. They discovered A to G point mutations at positions identical to *E.coli* 23S *rRNA* positions 2058 and 2059, and then called these positions 2143 and 2144 according to the entire *H. pylori* 23S *rRNA* sequence.²⁴

The present study focused on the three common point mutations, namely A2143G, A2142G and A2142C, which according to a sizable number of previous reports are the most common mutations associated with clarithromycin resistance. All of 20 Cla^R isolates had at least one of these three mutations. Therefore, there was an absolute association between these three point mutations in 23s

rRNA gene and Clarithromycin resistance in the isolates.

In agreement with the findings by Alarcon et al,¹⁶ the present study showed that the A2142C point mutation in 23s *rRNA* existed only on Cla^R isolates without A2142G or A2143G point mutations in 23s *rRNA* (table 3).

A number of other investigator reported other point mutations in 23s *rRNA* gene that were associated with clarithromycin resistance as well. For example Hao et al. in China reported three novel point mutations including C2245T, G2244A and T2289C that were associated with clarithromycin resistance in their local isolates.²⁵ Also, Khan et al. showed that T2182C point mutation in 23s *rRNA* was associated with clarithromycin resistance in Bangladesh.²⁶ Therefore, it is important to realize that the three common point mutations that the present study focused on are not the only reason of clarithromycin resistance, and there could be some other point mutations in 23s *rRNA* gene associated with such a resistance.

Some other mechanisms have been suggested for clarithromycin resistance, of which one is efflux pumps. Hirata et al. suggested a contribution of efflux pumps to the clarithromycin resistance in Japan.²⁷ Since there was no significant relation between gender, age, or the history of antibiotics consumption of the patients and resistance to clarithromycin, it seems that spontaneous mutations are responsible for such a resistance among the microbial population. The importance of such a resistance was revealed when a number of studies reported that resistance to clarithromycin was equal to the whole therapeutic regime failure.²⁸

Conclusion

The high rate of clarithromycin resistance in the isolates in the present study is a serious alarm, and in agreement with clinical colleagues' views that many of their patients do not respond to clarithromycin anymore. Point mutations in 23s *rRNA* are closely related to such a resistance. With daily increase in the use of clarithromycin in therapeutic regime for *H. pylori* in Iran, the rate of *H. pylori* resistance rate to the drug is increasing. Therefore, it seems necessary to do antibiotic susceptibility tests for *H. pylori* before therapy begins.

Acknowledgment

The authors would like to thank the Research Council of Kerman University of Medical

Sciences for their financial supports.

Conflict of Interest: None declared

References

- 1 Cameron EA, Powell KU, Baldwin L, et al. *Helicobacter pylori*: antibiotic resistance and eradication rates in Suffolk, UK, 1991–2001. *J Med Microbiol* 2004; 53: 535-8.
- 2 Liu Z, Shen J, Zhang L, et al. Prevalence of A2143G mutation of *H. pylori*-23S rRNA in Chinese subjects with and without clarithromycin use history. *BMC Microbiol* 2008; 8: 81.
- 3 Korn A, Garber A, Goodman S. Pharmacogenomics-based treatment of *Helicobacter pylori* infection. *Assessment program* 2008; 23: 1-21.
- 4 Soltermann A, Perrena A, Schmida S, et al. Assessment of *Helicobacter pylori* clarithromycin resistance mutations in archival gastric biopsy samples. *Swiss Med Wkly* 2005; 135: 327-32.
- 5 Occhialini A, Urdaci M, Doucet-populaire F, et al. Macrolide resistance in *Helicobacter pylori*: rapid detection of point Mutations and assays of macrolide binding to ribosomes. *Antimicrob Agents Chemother* 1997; 41: 2724-8.
- 6 Hultén K, Gibreel A, Sköld O, Engstrand L. Macrolide Resistance in *Helicobacter pylori*: Mechanism and Stability in Strains from Clarithromycin-Treated Patients. *Antimicrob Agents Chemother* 1997; 41: 2550-3.
- 7 Versalovic J, Shortridge D, Kibler K, et al. Mutations in 23S rRNA Are Associated with Clarithromycin Resistance in *Helicobacter pylori*. *Antimicrob Agents and Chemother* 1996; 40: 477-80.
- 8 Mégraud F. *H. pylori* antibiotic resistance: prevalence, importance, and advances in testing. *Gut* 2004; 53: 1374-84.
- 9 De Francesco V, Margiotta M, Zullo A, et al. Prevalence of primary clarithromycin resistance in *Helicobacter pylori* strains over a 15 year period in Italy. *J Antimicrob Chemother* 2007; 59: 783-5.
- 10 Mishra KK, Srivastava S, Garg A, Ayyagari A. Antibiotic susceptibility of *Helicobacter Pylori* clinical isolats: Comparative evaluation of disk-diffusion and E-test methods. *Curr Microbiol.* 2006; 53: 329-34.
- 11 Mohammadi M, Doroud D, Mohajerani N, Massarrat S. *Helicobacter pylori* antibiotic resistance in Iran. *World J Gastroenterol* 2005; 11: 6009-13.
- 12 Alarcón T, Domingo D, Prieto N, López-Brea M. PCR using 3-mismatched primers to detect A2142C mutation in 23S rRNA conferring resistance to clarithromycin in *Helicobacter pylori* clinical isolates. *J Clin Microbiol* 2000; 38: 923-5.
- 13 Savari M, Abdollahi H, Zahedi MJ, Darvish-Moghadam S, Hayat-Bakhah M. Antibiotic-resistance Patterns of *Helicobacter pylori* isolates Obtained from Patients in Kerman- 2009. *Journal of Kerman University of Medical Sciences* 2011; 18(1): 73-82. (In Persian)
- 14 Abdollahi H, Savari M, Zahedi MJ, Darvish-Moghadam S, Hayat-Bakhah MA. Study of *rdxA* gene deletion in metronidazole resistant and sensitive *Helicobacter pylori* isolates in Kerman, Iran. *Jundishapur J Microbiol* 2011; 4(2): 99-104.
- 15 Siavoshi F, Saniee P, Latifi-Navid S, et al. Increase in resistance rates of *H.pylori* isolates to metronidazole and tetracycline-comparison of three 3-year studies. *Arch Iranian med* 2010; 13: 177-87.
- 16 Kim KS, Kang JO, Eun CS, et al. Mutations in the 23S rRNA Gene of *Helicobacter pylori* Associated with Clarithromycin Resistance. *J Korean Med Sci* 2002; 17: 599-603.
- 17 Elviss NC, Owen RJ, Breathnach A, et al. *Helicobacter pylori* antibiotic-resistance patterns and risk factors in adult dyspeptic patients from ethnically diverse populations in central and south London during 2000. *J Med Microbiol* 2005; 54: 567-74.
- 18 Baglan PH, Bozdayi G, Ozkan M, et al. Clarithromycin Resistance Prevalence and *IcaA* Gene Status in *Helicobacter Pylori* Clinical Isolates in Turkish Patients with Duodenal Ulcer and Functional Dyspepsia. *J Microbiol* 2006; 44: 409-16.
- 19 Kohanteb J, Bazargana I, Saberi-Firoozi M, Mobasser A. Antimicrobial susceptibility testing of *Helicobacter pylori* to selected agents by agar dillution method in Shiraz, Iran. *Indian J Med Microbiol* 2007; 25: 374-7.
- 20 Grove D, Koutsouridis G. Increasing resistance of *Helicobacter pylori* to clarithromycin: is the horse bolting?. *Pathology* 2002; 34: 71-73.
- 21 Menninger R. Functional consequences of binding macrolides to ribosomes. *J Antimicrob Chemother* 1985; 16: 23-34.
- 22 Goldman RC, Zakula D, Flamm R, et al. Tight binding of clarithromycin, its 14-*R*-hydroxy metabolite, and erythromycin to *Helicobacter pylori* ribosomes. *Antimicrob Agents Chemother* 1994; 38: 1496-500.

- 23 Xia HX, Buckley M, Keane CT, O'Morain CA.. Clarithromycin resistance in *Helicobacter pylori*: prevalence in untreated dyspeptic patients and stability *in vitro*. *J antimicrob chemother* 1996; 37: 473-81.
- 24 Taylor D, Purych D, Lo T, Hiratsuka K. Cloning and sequence analysis of two copies of a 23S rRNA gene from *Helicobacter pylori* and association of clarithromycin resistance with 23S rRNA mutations. *Antimicrob Agents Chemother* 1997; 41: 2621-8.
- 25 Hao Q, Li Y, Zhang ZJ, et al. New mutation points in 23S rRNA gene associated with *Helicobacter pylori* resistance to clarithromycin in northeast China. *World J Gastroenterol* 2004; 10: 1075-7.
- 26 Khan R, Nahar S, Sultana J, et al. T2182C Mutation in 23S rRNA Is Associated with Clarithromycin Resistance in *Helicobacter pylori* Isolates Obtained in Bangladesh. *Antimicrob Agents Chemother* 2004; 48: 3567-9.
- 27 Hirata K, Suzuki H, Nishizawa T, et al. Contribution of efflux pumps to clarithromycin resistance in *Helicobacter pylori*. *J Gastroenterol Hepatol* 2010; 25: S75-9.
- 28 Tankovic J, Lamarque D, Lascols C, et al. Clarithromycin resistance of *Helicobacter pylori* has a major impact on the efficacy of the omeprazole-amoxicillin-clarithromycin therapy. *Pathol Biol (Paris)* 2001; 49: 528-33.

Archive of SID